Researchers sought to determine whether CCR7 alterations are associated with survival outcomes in patients with adult T-cell leukemia/lymphoma treated with mogamulizumab without HSCT.
Combination acalabrutinib, obinutuzumab, and venetoclax did not meet the prespecified activity threshold in the CLL2-BAAG trial.
Researchers sought to determine the long-term efficacy of cladribine in patients with hairy cell leukemia.
Researchers sought to determine whether tisagenlecleucel was effective would be effective in infant patients with B-ALL
Researchers sought to determine whether copy number variations would have prognostic value in patients with B-ALL.
Researchers sought to determine the long-term clinical experience of patients with treatment-naïve HCL between 1969 and 2018 treated with cladribine.
Researchers sought to determine outcomes with allo-HCT in patients with ALL over a 30-year study.
Researchers sought to determine the prognostic utility of KMT2A-PTD in patients with MDS and AML.
Seroconversion rates were low for patients receiving anti-CD20 therapy, CAR T-cell therapy, and transplants, as well as CLL patients taking ibrutinib.
Researchers sought to determine whether higher doses of tisagenlecleucel would improve survival outcomes among pediatric patients with relapsed/refractory B-ALL.
